{"id":"df-01","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action of DF 01 is not well understood, but it is believed to inhibit the activity of this enzyme, leading to a decrease in the production of a certain biomarker.","oneSentence":"DF 01 is a small molecule drug that targets the mechanism of action of a specific enzyme.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:32:29.391Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT03887702","phase":"PHASE3","title":"Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"2020-01-17","conditions":"Hepatitis B Infection, Malignant Solid Neoplasm","enrollment":4},{"nctId":"NCT03001193","phase":"PHASE2","title":"Effect of Tafoxiparin to Treat Primary Slow Progress of Labor Including Prolonged Latent Phase and Labor Arrest","status":"COMPLETED","sponsor":"Dilafor AB","startDate":"2016-12","conditions":"Labor, Obstetric","enrollment":361},{"nctId":"NCT00525733","phase":"NA","title":"Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2007-10","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT00391638","phase":"PHASE2, PHASE3","title":"Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2007-01","conditions":"Hepatitis B, HIV Infections","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tafoxiparin"],"phase":"phase_2","status":"active","brandName":"DF 01","genericName":"DF 01","companyName":"Dilafor AB","companyId":"dilafor-ab","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DF 01 is a small molecule drug that targets the mechanism of action of a specific enzyme. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}